As part of its strategy to grow in-licensed products, Elder Pharmaceuticals is focusing on enhancing its presence in pain management and treatment of chronic diseases. The company has identified chronic diseases like arthritis and cartilage disease for which it has made a specific arrangement with two foreign companies in order to market the products.
Besides, another area where the company is expanding its operations is on Nutraceuticals front, catering to cardiac, diabetic and kidney disease patients. Since the company is targeting to establish leadership for its various in-licensed products and at the same time trying to develop its own brand portfolio in the country, the drug major has adopted two pronged strategy for growth.
Elder Pharmaceuticals (EPL) has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.
